Citation Impact
Citing Papers
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
2008
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial
2011
Systemic Delivery of Microencapsulated 3-Bromopyruvate for the Therapy of Pancreatic Cancer
2014 StandoutNobel
Next Generation Sequencing of Serum Circulating Nucleic Acids from Patients with Invasive Ductal Breast Cancer Reveals Differences to Healthy and Nonmalignant Controls
2010
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Metastasis: from dissemination to organ-specific colonization
2009 Standout
Ferroptosis: molecular mechanisms and health implications
2020 Standout
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
2008
Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
2010
Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy
2007
Netting neutrophils in autoimmune small-vessel vasculitis
2009 Standout
Pancreatic cancer
2004 Standout
Targeting hypoxia in cancer therapy
2011 Standout
Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer
2010
DAMPs, ageing, and cancer: The ‘DAMP Hypothesis’
2014
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
Chemical Radiosensitizers for Use in Radiotherapy
2007
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
2012 Standout
Pancreatic cancer
2020 Standout
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer
2005
Impact of platinum‐based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients
2010
Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy
2012
Advanced pancreatic carcinoma: current treatment and future challenges
2010
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Pretreatment CA 19-9 Level as a Prognostic Factor in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine
2002
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
Effect of Solar Particle Event Radiation and Hindlimb Suspension on Gastrointestinal Tract Bacterial Translocation and Immune Activation
2012 StandoutNobel
Pancreatic cancer
2016 Standout
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010
2011
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Nasopharyngeal carcinoma
2019 Standout
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Nanocarriers for delivery of platinum anticancer drugs
2013
Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma
2001
Pancreatic Adenocarcinoma
2014 Standout
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
2011
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Circulating Nucleic Acids in Plasma and Serum
2008
Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer
2016
HMGB1 in health and disease
2014
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Nucleosomal DNA Fragments in Autoimmune Diseases
2006
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Neutrophil extracellular traps in cancer progression
2014
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
2008
Wound Trauma Increases Radiation-Induced Mortality by Activation of iNOS Pathway and Elevation of Cytokine Concentrations and Bacterial Infection
2010
Pancreatic Cancer
2010 Standout
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells
2010 Standout
A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry–Based Glycoproteomics
2020 StandoutNobel
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
2005
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
2014 Standout
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
2011
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Circulating nucleic acids (CNAs) and cancer—A survey
2006
Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy
2008
Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity
2008
The Clavien-Dindo Classification of Surgical Complications
2009 Standout
Glycosylation in cancer: mechanisms and clinical implications
2015 Standout
Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts
2010
Pancreatic cancer
2011 Standout
The Human Cancer Antigen Mesothelin Is More Efficiently Presented to the Mouse Immune System when Targeted to the DEC‐205/CD205 Receptor on Dendritic Cells
2009 StandoutNobel
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
2006
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
Apoptosis: A Target for Anticancer Therapy
2018 Standout
Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
2007
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?
2008
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
2003
Randomized phase II /III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS ‐PC Study
2015
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
2010
Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review
2009
The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma
2017
Perspectives on Anti-Glycan Antibodies Gleaned from Development of a Community Resource Database
2016
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001
2008
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Analysis of nanoparticle delivery to tumours
2016 Standout
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
Therapeutic applications of curcumin for patients with pancreatic cancer.
2014
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma
2006
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Clinical Translation of Nanomedicine
2015
Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology
2005
Works of Ralf Wilkowski being referenced
Detrimental Immunologic Effects of Preoperative Chemoradiotherapy in Advanced Rectal Cancer
2003
Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer
2006
Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer
2007
Nucleosomes in Pancreatic Cancer Patients during Radiochemotherapy
2005
Are Serial CA 19-9 Kinetics Helpful in Predicting Survival in Patients with Advanced or Metastatic Pancreatic Cancer Treated with Gemcitabine and Cisplatin?
2003
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer
2010
Randomized trial with early-stage Hodgkin's disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone
1996
Clinical Relevance of Circulating Nucleosomes in Cancer
2008
Feasibility of Photofrin II as a Radiosensitizing Agent in Solid Tumors – Preliminary Results
2006
Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer
2010
Effect of Chemoradiotherapy with Gemcitabine and Cisplatin on Locoregional Control in Patients with Primary Inoperable Pancreatic Cancer
2004
Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer
2008
CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin.
1999
Nucleosomes in Colorectal Cancer Patients during Radiochemotherapy
2006
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
2006
Randomized phase II trial comparing gemcitabine/cisplatin-based chemoradiotherapy (CRT) to 5-FU-based CRT in patients with locally advanced pancreatic cancer
2006